Fig. 5From: Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomasDiagnostic performance of the models and methylation levels in the model validation cohort (n = 105). A Methylation levels of the final 20 selected biomarkers in the model validation cohort (*Wilcoxon rank-sum test p value < 0.05). B ROC curve analysis and AUC for the three models evaluated for CRC screening, derived by leave-one-out cross-validation (GALNT9: CG3; UPF3A: CG15; WARS: CG5; and LDB2: CG24). The red dots indicate the sensitivity and specificity values for the best cutoffs based on the Youden index method. C Serum methylation levels of CG3-GALNT9, CG15-UPF3A, CG5-WARS, and CG24-LDB2 in the model validation cohort (n = 105), and in lung, breast, kidney, prostate, and ovarian cancer cases (n = 16). D Methylation levels and classification performance (ROC curve) of the SEPT9 promoter. The red dot indicates the best sensitivity and specificity values (Youden index). E Comparison of methylation levels between matched serum and plasma samples. AUC: area under the curve; NN: no neoplasia; AA: advanced adenomas; and CRC: colorectal cancerBack to article page